US FDA Neuroscience Office In Spotlight With Donanemab Delay, Relyvrio Trial Failure

 
• By Sue Sutter
  
Crossbow
FDA's Office of Neuroscience is feeling some recoil from its use of regulatory flexibility in two neurodegenerative diseases. • Source: Shutterstock

More from Post-Marketing Regulation & Studies

More from Product Reviews